Back to News
Market Impact: 0.35
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Source: 247wallst.com
Healthcare & BiotechCompany FundamentalsInvestor Sentiment & Positioning
Novartis' failed cholesterol trial is pressuring the Lp(a) drug-development class in Tuesday trading, with Amgen hit harder than other large-cap peers. The result raises investor concerns over the clinical and commercial outlook for Lp(a)-targeting therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
AMGN-0.55
NVS-0.75
More News
- Cholesterol drug setback casts doubt over multibillion-dollar race
- Attacks Halt Saudi Energy Sites, Novartis Drops Most in 6 Years | The Opening Trade 9/8/2026
- Pharma major plummets over 10% after third trial disappointment in a week
- Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
- Novartis Sees Avidity Drug Suffer Third Clinical-Trial Setback
- Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries